Diffuse Pulmonary Arteriovenous Fistulas With Pulmonary Arterial Hypertension

Case Report and Review

Rong Jiang, MD, Su-Gang Gong, MD, Bigyan Pudasaini, MS, Qin-Hua Zhao, MD, Lan Wang, MD, Jing He, MD, and Jin-Ming Liu, PhD

Abstract: Pulmonary arteriovenous fistulas (PAVFs) are rare. Diffuse type PAVFs with pulmonary arterial hypertension (PAH) are even rarer and can elude anatomy imaging like a plain chest film or a computed tomography. The rapid blood flow that ensues due to lack of a capillary bed leads to various degrees of ischemia depending on the number and size of the PAVF. This is a case report of diffuse PAVF in a patient with PAH.

This case report describes a patient with recurrent hemoptysis and chest pain. Systemic examination was unremarkable except for P2 attenuation on auscultation. Echocardiography showed confirmed pulmonary hypertension with mild dilation of right atrium and ventricle and a tricuspid regurgitation pressure gradient of 40 mm Hg and ruled out congenital heart diseases. Right heart catheterization revealed precapillary PAH with mean pulmonary arterial pressure of 88 mm Hg. Pulmonary angiography showed enlarged pulmonary arterial trunk and diffuse spiral tortuous pulmonary arterial branches indicating diffuse PAVFs. The patient was diagnosed as PAH and began treatment of 25 mg tid of sildenafil.

The case highlights a rare and unique presentation of PAH.

INTRODUCTION

Pulmonary arteriovenous fistulas (PAVFs) are abnormal pulmonary vascular structures that connect a pulmonary artery to a pulmonary vein, bypassing the normal capillary bed resulting in an intrapulmonary right-to-left shunt. PAVFs may be congenital or acquired with a majority being associated with hereditary hemorrhagic telangiectasia (HHT) which is caused by mutations in Endoglin (HHT 1) and activin receptor-like kinase (ALK1) (HHT 2). Despite gene identification HHT remains a clinical diagnosis with clinical diagnostic criteria. The majority of non-HHT-related PAVFs are idiopathic, but other etiologies include chest trauma, Fanconi syndrome, amyloidosis, and infections like schistosomiasis and actinomycosis. Clinically, PAVF is generally classified into 2 types: focal and diffuse. Compared with the local type, the diffuse type is rarer, more severe and therapy is limited. Reports on diffuse PAVF with pulmonary artery hypertension (PAH) are rare.

CASE REPORT

A 28-year-old male presented with an 8-year history of recurrent hemoptysis and a year of chest pain. Systemic examination was unremarkable except for P2 attenuation on auscultation. He had no digital clubbing and no telangiectasia. Arterial blood gas showed partial pressure of arterial oxygen (PaO2) of 79 mm Hg and arterial oxygen saturation (SaO2) of 95.7% at room air. N-terminal pro-B-type natriuretic peptide (NT-proBNP): 33 pg/mL (0–125 pg/mL). Electrocardiogram showed right axis derivation and echocardiography showed confirmed pulmonary hypertension with mild dilation of right atrium and ventricle and a tricuspid regurgitation pressure gradient (TPG) of 40 mm Hg. Congenital heart conditions including atrial septal defect, ventricular septal defect, and other intracardiac shunts were ruled out by echocardiography as well. There were no differences in SaO2 of lower and upper extremities, which combing echocardiography may rule out patent ductus arteriosus. Connective tissue disease serology and thyroid function revealed negative. The patient had no history of chronic lung diseases. He has excellent pulmonary function [Forced inspiratory vital capacity (FVC) = 4.04 L, FEV1 (pred %) = 83.3, FEV1/FVC = 0.78, and DLCO (pred %) = 90.9 mL/min per mm Hg]. A computed tomography pulmonary angiogram demonstrates wedge shadow near the pleura and along the airway distribution around with flame fuzzy shadow in the upper lobes (Figure 1) and excluded chronic thromboembolic disease. Right heart catheterization (RHC) revealed precapillary pulmonary arterial pressure (PAP) (right atrial pressure [RAP]): 6–1/1 mm Hg; right ventricle pressure [RVP]: 144/–10/11 mm Hg; PAP: 139/59/88 mm Hg; pulmonary arterial wedge pressure: 17/4/8 mm Hg; cardiac output: 5.53 L/min; cardiac index: 3.48 L/min per m2; pulmonary vascular resistance: 14.47 wood Units) without vasodilatory response to inhaled iloprost. Pulmonary angiography showed enlarged...
pulmonary artery trunk and diffuse spiral tortuous pulmonary arterial branches indicting diffuse PAVFs (Figure 2). Bronchography showed tortuous and dilated internal thoracic artery and bronchial artery and peripheral small vessels with diffuse PAVFs (Figure 3). He was diagnosed as PAH and began treatment of 25 mg tid of sildenafil.

One year later, the patient was followed up by telephone, he told us his exercise tolerance had improved and had no symptoms of hemoptysis with treatment of sildenafil.

DISCUSSION

We report a patient with diffuse PAVFs with severe PAH. PAVFs are rare, autopsy reports describing only 3 in 15,000 autopsies performed. The approximate incidence of PAVF has been described to be 2 to 3 per 100,000 with a male-to-female ratio of approximately 1:1.5 to 1.8. Most solitary PAVFs are seen in the lower lobes, with the left lower lobe being the most common location. The majority of multiple PAVFs are also confined to the lower lobes, with the incidence of bilateral PAVFs ranging from 8% to 20%. The abnormal segment between the pulmonary artery and the pulmonary vein is fragile and may rupture and bleed as the PAVF size increases, manifesting as hemoptysis or a hemothorax. Small subsets of patients have a more diffuse and severe type of PAVF that involves segmental pulmonary arteries. Diffuse PAVFs result in severe hypoxemia and are challenging to treat.

Most PAVFs are hereditary, with about 90% occurring in patients with HHT. The majority of non-HHT-related PAVFs are idiopathic, but other etiologies include chest trauma, Fanconi syndrome, amyloidosis, and infections such as schistosomiasis and actinomycosis. PAVFs also occur secondary to hepatopulmonary syndrome (HPS) or bidirectional cavopulmonary shunts (BCPS). The majority of patients with HHT have HHT1 because of mutations in endoglin (ENG) encoding endoglin or HHT 2 because of mutations in ACVRL1 encoding ALK1. PAH occurs almost exclusively in individuals with ACVRL1 mutation. The genes mutated in HHT encode proteins involved in the transforming growth factor β (TGF-β) superfamily signaling pathway. The TGF-β pathway is important in...
regulating proliferation, differentiation, adhesion, and migration which are key processes in angiogenesis.

This patient denied any history of hepatic diseases, epistaxis, telangiectasia, visceral lesions (except pulmonary malformations), and family history. According to mainstay of the Curacao criteria, the patient was unlikely to have HHT. Thus, although unusual the diagnosis was idiopathic PAH.

In this case report, despite of high PAP by RHC, the RAP did not increase accordingly which may be due to compensated RV systolic and diastolic function to pulmonary vascular diseases. Early in PAH, the adaptive ventricular remodeling and preserved right ventricle reserve could adapt PAP and maintain RVP and RAP. The good exercise tolerance and normal NT-proBNP level implied the patient had adaptive right ventricle reserve. It may explain why the patient did not have significant increased RAP.

For this patient, a TPG by echocardiography was 40 mm Hg while systolic PAP [pulmonary arterial systolic pressure (PASP)] by RHC was 139 mm Hg. The TPG was estimated based on the modified Bernoulli equation and was then added to an estimate of RAP to obtain an estimate of PASP in the absence of right ventricular outflow obstruction; however, Bernoulli method systematically underestimated or overestimated the PASP when actual PAP was too high or too low. Echocardiography has its inherent limitation; echocardiography may frequently be inaccurate in estimating PAP in patients being evaluated for PH.

CONCLUSIONS

The case highlights a rare and unique presentation of PAH. Most cases of PAVF can remain asymptomatic until the third or fourth decade of life. Moreover, the shunting may facilitate passage of emboli into the cerebral circulation thereby being implicated in various other pathologies. Although prognosis is poor, such patients would benefit tremendously by early detection and appropriate management.

CONSENT

The patient signed informed consent for the publication of this case report and any accompanying images. Ethical approval of this study was obtained by the ethics committee of Shanghai Pulmonary Hospital.

REFERENCES

1. Swanson KL, Prakash UB, Stanson AW. Pulmonary arteriovenous fistulas: Mayo Clinic experience, 1982–1997. Mayo Clin Proc. 1999;74:671–680.
2. Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax. 1999;54:714–729.
3. Dines DE, Armas RA, Bernatz PE, et al. Pulmonary arteriovenous fistulas. Mayo Clin Proc. 1974;49:460–465.
4. Dines DE, Seward JB, Bernatz PE. Pulmonary arteriovenous fistulas. Mayo Clin Proc. 1983;58:176–181.
5. Gossage JR, Kanj G. Pulmonary arteriovenous malformations. A state of the art review. Am J Respir Crit Care Med. 1998;158:643–661.
6. Guttmacher AE, Marchuk DA, White RJ Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995;333:918–924.
7. Prager RL, Laws KH, Bender HW Jr. Arteriovenous fistula of the lung. Ann Thorac Surg. 1983;36:231–239.
8. Taxman RM, Halloran MJ, Parker BM. Multiple pulmonary arteriovenous malformations in association with Fanconi’s syndrome. Chest. 1973;64:118–120.
9. De Faria JL, Czapski J, Leite MO, et al. Cyanosis in Manson’s schistosomiasis; role of pulmonary schistosomatic arteriovenous fistulas. Am Heart J. 1957;54:196–204.
10. Sloan RD, Cooley RN. Congenital pulmonary arteriovenous aneurysm. Am J Roentgenol Radium Ther Nucl Med. 1953;70:183–210.
11. Vase P, Holm M, Arendrup M. Pulmonary arteriovenous fistulas in hereditary hemorrhagic telangiectasia. Acta Med Scand. 1985;218:105–109.
12. Hodgson CH, Kaye RL. Pulmonary arteriovenous fistula and hereditary hemorrhagic telangiectasia: a review and report of 35 cases of fistula. Dis Chest. 1963;43:449–455.
13. Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet. 2006;43:97–110.
14. Faughnan ME, Granton JT, Young LH. The pulmonary vascular complications of hereditary haemorrhagic telangiectasia. *Eur Respir J*. 2009;33:1186–1194.

15. Cartin-Ceba R, Swanson KL, Krowka MJ. Pulmonary arteriovenous malformations. *Chest*. 2013;144:1033–1044.

16. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. *Nat Genet*. 1994;8:345–351.

17. Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. *Nat Genet*. 1996;13:189–195.

18. McDonald J, Bayrak-Toydemir P, Pyeritz RE. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. *Genet Med*. 2011;13:607–616.

19. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). *Am J Med Genet*. 2000;91:66–67.

20. Vonk-Noordegraaf A, Haddad F, Chin KM, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. *J Am Coll Cardiol*. 2013;62: D22–D33.

21. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr*. 2010;23:685–713 quiz 86-8.

22. Falahatpisheh A, Rickers C, Gabbert D, et al. Simplified Bernoulli’s method significantly underestimates pulmonary transvalvular pressure drop. *J Magn Reson Imaging*. 2015.

23. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. *Am J Respir Crit Care Med*. 2009;179:615–621.